As of 2024-12-12, the Relative Valuation of Oncopeptides AB (ONCO.ST) is (38.90) SEK. This relative valuation is based on P/E multiples. With the latest stock price at 1.58 SEK, the upside of Oncopeptides AB based on Relative Valuation is -2565.0%.
The range of the Relative Valuation is (27.80) - (45.93) SEK.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 20.8x - 37.1x | 31.2x |
| Forward P/E multiples | 20.0x - 34.4x | 27.0x |
| Fair Price | (27.80) - (45.93) | (38.90) |
| Upside | -1861.9% - -3010.6% | -2565.0% |
| Date | P/E |
| 2024-12-04 | -1.16 |
| 2024-12-03 | -1.19 |
| 2024-12-02 | -1.17 |
| 2024-11-29 | -1.24 |
| 2024-11-28 | -1.26 |
| 2024-11-27 | -1.24 |
| 2024-11-26 | -1.13 |
| 2024-11-25 | -1.12 |
| 2024-11-22 | -1.15 |
| 2024-11-21 | -1.13 |
| 2024-11-20 | -1.11 |
| 2024-11-19 | -1.08 |
| 2024-11-18 | -1.08 |
| 2024-11-15 | -1.11 |
| 2024-11-14 | -1.13 |
| 2024-11-13 | -1.12 |
| 2024-11-12 | -1.15 |
| 2024-11-11 | -1.16 |
| 2024-11-08 | -1.14 |
| 2024-11-07 | -1.19 |
| 2024-11-06 | -1.55 |
| 2024-11-05 | -1.56 |
| 2024-11-04 | -1.57 |
| 2024-11-01 | -1.56 |
| 2024-10-31 | -1.56 |
| 2024-10-30 | -1.59 |
| 2024-10-29 | -1.60 |
| 2024-10-28 | -1.60 |
| 2024-10-25 | -1.62 |
| 2024-10-24 | -1.56 |
| 2024-10-23 | -1.56 |
| 2024-10-22 | -1.54 |
| 2024-10-21 | -1.56 |
| 2024-10-18 | -1.56 |
| 2024-10-17 | -1.57 |
| 2024-10-16 | -1.57 |
| 2024-10-15 | -1.56 |
| 2024-10-14 | -1.56 |
| 2024-10-11 | -1.59 |
| 2024-10-10 | -1.59 |
| 2024-10-09 | -1.59 |
| 2024-10-08 | -1.58 |
| 2024-10-07 | -1.61 |
| 2024-10-04 | -1.59 |
| 2024-10-03 | -1.64 |
| 2024-10-02 | -1.60 |
| 2024-10-01 | -1.59 |
| 2024-09-30 | -1.60 |
| 2024-09-27 | -1.63 |
| 2024-09-26 | -1.64 |